NCT07294092

Ketamine and Propofol NeuroImaging

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Keith M Vogt · Academic / Other
• Sex: All
• Age: 18 Years – 59 Years
• Healthy volunteers: Accepted

Summary

This is a multi-visit which will collect MRI (pictures of the brain) and EEG (brain waves) data to determine changes in brain connectivity and brain activity for memory formation and pain perception while receiving the commonly-used anesthetic agents ketamine and propofol, both alone and in combination.

Detailed description

There are four independent drug-administration sessions, visits 1, 3, 5, and 7. In all four of these sessions, both drugs are received, but in two different sequences. Two of these are EEG sessions and two are MRI sessions. Both EEG and MRI will have the same two drug orderings: * Propofol alone, followed by ketamine and propofol together * Ketamine alone, followed by propofol and ketamine together Assignment to propofol alone first, versus ketamine alone first will be randomized. But, all subjects will be assigned to receive both drug orderings under both EEG monitoring and MRI acquisition. A follow-up memory testing visit will occur the day after each MRI/EEG session, on visits 2, 4, 6, and 8. No drugs are given during the next-day testing sessions.

Conditions

• Anesthesia
• Pain

Interventions

Type	Name	Description
DRUG	Propofol	Subjects will receive an intravenous infusion of this drug, during portions of the study.
DRUG	Ketamine	Subjects will receive an intravenous infusion of this drug, during portions of the study.
DEVICE	Peripheral Nerve Stimulation	Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with specific experimental events.

Timeline

• Start date: 2026-04-10
• Primary completion: 2028-08-01
• Completion: 2028-08-02
• First posted: 2025-12-19
• Last updated: 2026-04-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study